Last $9.36 USD
Change Today +0.25 / 2.74%
Volume 607.9K
INO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Open
$9.14
Previous Close
$9.11
Day High
$9.57
Day Low
$9.14
52 Week High
02/24/14 - $15.80
52 Week Low
05/12/14 - $7.48
Market Cap
567.1M
Average Volume 10 Days
890.7K
EPS TTM
$-0.82
Shares Outstanding
60.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INOVIO PHARMACEUTICALS INC (INO)

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

71 Employees
Last Reported Date: 03/17/14
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $852.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.0K
Chief Operating Officer
Total Annual Compensation: $409.8K
Chief Medical Officer
Total Annual Compensation: $414.3K
Compensation as of Fiscal Year 2013.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) added to NASDAQ Biotechnology Index

Inovio Pharmaceuticals, Inc. will be added to the NASDAQ Biotechnology Index.

Inovio Pharmaceuticals, Inc. Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers

Inovio Pharmaceuticals, Inc. announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. Because high levels of hTERT expression are found in 85% of human cancers, Inovio's cancer candidate holds the potential as a broad spectrum cancer therapeutic. A previously published study of this product showed that administration in monkeys, whose TERT is 96% similar to human TERT, generated strong and broad TERT-specific immune responses and demonstrated the potential to eliminate tumor cells. Mice immunized with Inovio's DNA immunotherapy experienced delayed tumor growth, tumor shrinkage, and longer overall survival compared with non-immunized mice. This human trial is an open label, dose escalation study in subjects with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other treatments including chemotherapy and radiation. Approximately 54 subjects will be enrolled into one of six treatment groups and receive INO-1400 alone or in combination with INO-9012, Inovio's immune activator. The study will be conducted at the University of Pennsylvania's Abramson Cancer Center, which will fund all site-specific clinical study costs. Lung, breast, and pancreatic cancer mortality rates are ranked first, third, and fourth, respectively, among cancer types in the United States, despite improvement in detection and treatment. In each of these three cancer types, significant numbers of patients undergo surgical resection and adjuvant therapy with an attempt at cure, but only a fraction remain in remission. This study will evaluate Inovio's novel immunotherapy with the ultimate goal of reducing the risk of relapse in these patients. The primary objective of this study is to evaluate the safety and tolerability of INO-1400 alone or in combination with INO-9012, delivered intramuscularly in subjects with high-risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy. The secondary objectives are to evaluate cellular and humoral immune responses, measure time to disease progression, and evaluate immunotherapy-induced changes in subjects.

Inovio Pharmaceuticals Appoints Zane Yang as Vice President, Clinical Development, Oncology

Inovio Pharmaceuticals, Inc. announced the appointment of Zane Yang, as vice president, clinical development, Oncology. In this position, he will be responsible for advancing Inovio's oncology portfolio of DNA immunotherapy's through clinical trials to commercialization. He will report to Mark Bagarazzi, Inovio's chief medical officer. Yang joins Inovio from Janssen Pharmaceuticals, where he was director, Oncology Medical Affairs in the U.S. Yang led the prostate cancer and solid tumor therapeutic area including development and commercialization of Zytiga®, for the treatment of metastatic castration-resistant prostate cancer. Prior to Janssen, he was Director of Global Medical Affairs and Clinical Development at Novartis Oncology, and Director of Clinical Development at Merck & Co.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $9.36 USD +0.25

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $7.97 USD +0.40
Dynavax Technologies Corp $15.62 USD +0.27
Peregrine Pharmaceuticals Inc $1.45 USD +0.05
Vical Inc $1.07 USD +0.04
ZIOPHARM Oncology Inc $4.90 USD +0.14
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.0x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit www.inovio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.